The healthcare industry has to coordinate the creation of new incentives to push the system away from fee-for-service, said Leah Binder. She used bundled payments as an example.
“Every other industry has figured out some way or another how to bundle services and offer the consumer one price,” Binder said. “We’ve got to do that in healthcare. Yes, it’s incredibly difficult. It’s got to be done.”
What occurs as a result of creating strong incentives to move away from volume-based payment is that entrepreneurs will solve issues that arise and create new industries, said Margaret E. O’Kane, MHA. However, she added that the short-term transition will be “awkward,” which always happens when there are big changes.
As for other innovative payments models, CalPERS is using reference pricing for a number of procedures, such as hip and knee replacement, colonoscopies, and other surgical procedures, said Austin Frakt, PhD. CalPERS finds quality providers that policy holders will have plenty of access to and sets the price for a procedure. CalPERS won’t pay more than that price, but the enrollees can go elsewhere to receive care and if it costs more, then they pay the difference out of pocket. This has been successful for CalPERS, but it won’t work everywhere.
“You can’t do this in markets where you don’t have enough providers to have the variety so people can make these kinds of decisions,” Dr Frakt explained. “You can’t do it in places where you don’t have the transparency on price and quality. So there are limitations.”
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More